uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
Show others and affiliations
2009 (English)In: American Heart Journal, ISSN 0002-8703, E-ISSN 1097-6744, Vol. 157, no 5, 805-810 p.Article in journal (Refereed) Published
Abstract [en]

Vitamin K antagonists (VKAs) are effective for stroke prevention in patients with atrial fibrillation (AF) but are difficult to use. Dabigatran etexilate is a prodrug that is rapidly converted to the active direct thrombin inhibitor dabigatran. It is administered in a fixed dose without laboratory monitoring and is being compared with warfarin (international normalized ratio 2-3) in the RE-LY trial. Two doses of dabigatran (110 and 150 mg BID) are being evaluated. RE-LY is a phase 3, prospective, randomized, open-label multinational (44 countries) trial of patients with nonvalvular AF and at least 1 risk factor for stroke. Recruitment concluded with a total of 18,113 patients. Patients who were VKA-naive and experienced are included in balanced proportions. The primary outcome is stroke (including hemorrhagic) or systemic embolism. Safety outcomes are bleeding, liver function abnormalities, and other adverse events. Adjudication of end points is blinded to drug assignment. The trial is expected to accrue a minimum of 450 events with a minimum 1-year of follow-up. RE-LY is the largest AF stroke prevention trial yet undertaken. It is unique because it includes equal numbers of VKA-experienced and naive patients and evaluates 2 different dosages of dabigatran, which may allow tailoring of dosing to individual patient needs. The worldwide site distribution and broad range of stroke risk further increase the general applicability of the trial. Results are expected in 2009.

Place, publisher, year, edition, pages
2009. Vol. 157, no 5, 805-810 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-105110DOI: 10.1016/j.ahj.2009.02.005ISI: 000265987800010PubMedID: 19376304OAI: oai:DiVA.org:uu-105110DiVA: diva2:220516
Available from: 2009-06-01 Created: 2009-06-01 Last updated: 2012-07-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Oldgren, JonasWallentin, Lars
By organisation
Department of Medical SciencesUCR-Uppsala Clinical Research Center
In the same journal
American Heart Journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 213 hits
ReferencesLink to record
Permanent link

Direct link